摘要
目的:评估低剂量多西紫杉醇单药每周方案在老年转移性乳腺癌(metastatic breast cancer,MBC)患者中的疗效和不良反应。方法:对28例老年MBC患者,用多西紫杉醇30mg/m2,静脉滴注,第1、8天,每3周重复,最多6周期。结果:28例患者共完成120周期的化疗,其中完全缓解者1例(3.6%),部分缓解者8例(28.6%),有效率为32.1%(95%CI:14.8%～49.4%),肿瘤控制率为71.4%。既往未用过化疗的患者有效率高于用过化疗的患者(P<0.05)。最常见的不良反应为血液学毒性。至随访结束,中位疾病进展时间为9.0个月,中位总生存期为15.0个月。结论:低剂量多西紫杉醇单药每周方案在MBC老年患者中较为有效且耐受性良好。
Objective： To evaluate the efficacy and adverse reaction induced by a weekly schedule of low dose of docetaxel （DOC） for elderly patients with metastatic breast cancer （MBC）. Methods： Twenty eight MBC patients were treated with docetaxel alone at a dose of 30 mg/m2 on day 1 and day 8, which were repeated every 3 weeks for a maximum of 6 cycles. Results：Twenty-eight patients completed 120 cycles of chemotherapy. In the 28 evaluable patients, 1 （3.6%） patient achieved a complete response, and 8 （28.6%） patients had a partial response, with an overall effective rate of 32.1% （95% CI： 14.8%-49.4% ） and tumor control rate of 71.4%. The response rate in chemotherapy-naive patients was higher than that in patients who were pretreated with chemotherapy. The most common adverse events were hematologic toxicities. The median time to progression was 9.0 months （ 95% CI ： 8.1-9.9 ） , and the overall survival time was 15.0 （95% CI： 10.2-19.9） months at the end of follow-up period. Conclusion：A weekly schedule of low dose of docetaxel （DOC） was effective and well-tolerated for elderly MBC patients.
出处
《肿瘤》
CAS
CSCD
北大核心
2009年第1期91-93,共3页
Tumor
